Editing Donepezil Hydrochloride (section)

==Drug Management==
===Monitoring===
*Acetylcholinesterase inhibitor may increase gastric acid secretion, so patients should be monitored closely for GI bleeding, especially those receiving concurrent NSAID drugs.
*Check body weight regularly
*Monitor the cognitive, global functions, and ADL activities
*Monitor the sleeping quality

===Drug interaction===
{|class="wikitable"
!style="text-align: left"| CYP2D6 inhibitors:
SSRI, such as Paroxetine quinidine
|May increase plasma-donepezil concentration, increasing the risk of severe adverse reactions.
|-
!style="text-align: left"| May increase plasma-donepezil concentration, 
increasing the risk of severe adverse reactions.
|May increase plasma-donepezil concentration, increasing the risk of severe adverse reactions
|-
!style="text-align: left"| CYP3A4 inducers & CYP2D6 inducers: 
Rifampicin, Phenytoin, Carbamazepine
|May reduce plasma-donepezil concentration
|}

===Caution===
*Cardiovascular conduction disorders such as sick-sinus syndrome
*Susceptibility to peptic ulcers
*Asthma, chronic obstructive pulmonary disease
*People who have a predisposition to seizures
*Concomitant antipsychotic treatment – increased risk of neuroleptic malignant syndrome

===Contraindications===
It is contraindicated in patients with a known hypersensitivity to donepezil hydrochloride.

===Hepatic and Renal impairment===
A similar dose schedule can be followed for patients with renal or mild to moderate hepatic impairment as clearance of donepezil is not significantly affected by these conditions.

===Effects on ability to drive and use machinery===
Donepezil can cause fatigue, dizziness and muscles, mainly when initiating or increasing the dose. The treating doctor should routinely evaluate the ability of patients on donepezil to continue driving or operating complex machines.